Damora Therapeutics (DMRA) Proxy filing summary

Executive summary

• Annual meeting scheduled for June 17, 2026, with voting open until June 16, 2026, at 11:59 PM ET.

• Shareholders can access proxy materials online or request paper/email copies by June 3, 2026.

• Meeting will be held virtually, allowing remote participation and voting.

Voting matters and shareholder proposals

• Election of two Class III director nominees, Michael Landsittel and Cameron Turtle, D. Phil., to serve until the 2029 annual meeting.

• Advisory vote on the compensation of named executive officers.

• Advisory vote on the frequency of future say-on-pay votes, with the board recommending an annual vote.

• Ratification of Ernst & Young LLP as independent auditor for the fiscal year ending December 31, 2026.

• Provision for other business to be addressed as may properly come before the meeting.

Board of directors and corporate governance

• Board recommends voting in favor of all director nominees and proposals.